Forest Labs, Glenmark End Blood Pressure Drug IP Fight

Law360, New York (January 3, 2013, 12:19 PM EST) -- Pharmaceutical company Forest Laboratories Inc. said Wednesday it had agreed to drop patent infringement claims in a multidistrict litigation against generic-drug maker Glenmark Pharmaceuticals Ltd. over beta-blocker Bystolic after the two reached a licensing agreement for the drug.

Forest said it would give Glenmark a license allowing the company to release a generic version of nebivolol, the active ingredient in Bystolic, either when the U.S. Food and Drug Administration approves Glenmark's abbreviated new drug application or three months prior to the expiration of Forest's patent, whichever...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.